Life Sciences

  • May 19, 2026

    PTAB Ends Repetitive Challenges To Mercury Removal IP

    The Patent Trial and Appeal Board has tossed a pair of challenges to mercury removal patents owned by Birchtech Corp., saying the challengers were prioritizing separate bids to invalidate the same patents.

  • May 19, 2026

    Fed. Circ. Rehearing Sought In $18M Penile Implant Dispute

    The Federal Circuit has been asked to have another look at a decision that largely reversed a California federal jury verdict that awarded $18.3 million to International Medical Devices Inc. in a trade secret case related to penile implants.

  • May 19, 2026

    Mentari, InMed Merge In Deal Backed By $290M Funding

    InMed Pharmaceuticals Inc. on Tuesday announced plans to merge with migraine prevention drugmaker Mentari Therapeutics Inc. in an all-stock deal that is backed by a $290 million private placement and was guided by three law firms.

  • May 19, 2026

    Novo Nordisk Says Investor Suit Pleadings Are Impermissible

    Novo Nordisk AS urged a New Jersey federal court to toss a proposed securities class action accusing it of misleading investors about its 2025 revenue outlook, arguing that the plaintiffs failed to plead any materially false or misleading statements.

  • May 19, 2026

    Fed. Circ. Restores 2 Patent Suits On Same Standing Issue

    The Federal Circuit on Tuesday reinstated a pair of patent infringement suits from patent owners that licensed their intellectual property to other parties, finding that the companies met the minimum constitutional requirements to show they had standing to sue.

  • May 19, 2026

    Feds Say High Court Should Skip Religious Bias Vax Fight

    The U.S. solicitor general urged the U.S. Supreme Court not to wade into a religious bias case challenging New York's COVID-19 vaccine mandate for healthcare workers, arguing that a Second Circuit decision backing the case's dismissal did not undermine federal civil rights law.

  • May 18, 2026

    Comic Gets Serious About Mom's Cancer At J&J Talc Trial

    A comedian who testified Monday at a California bellwether trial over claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer wiped away tears as he talked about his late mother, saying his emotions are "a little unusual" because he spends most of his time trying not to be serious.

  • May 18, 2026

    Squires, Stewart Zero In On PTAB's Burden Of Proof At Panel

    The leaders of the U.S. Patent and Trademark Office on Monday asked intellectual property experts to wade into debates over the Patent Trial and Appeal Board, focusing in part on whether switching to a stricter burden of proof would address disparate outcomes between the board and district court.

  • May 18, 2026

    Woman Says Spinal Device Caused Permanent Nerve Damage

    The maker of a spinal cord stimulation technology to treat chronic pain faces a federal lawsuit from a Colorado woman who claims that the technology caused her permanent nerve damage and that the device has unacceptable rates of failure nationwide.

  • May 18, 2026

    Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit

    An Illinois appeals panel on Monday affirmed summary judgment in favor of AbbVie in a suit alleging one of its eye stents caused a man's eye injuries, finding the patient failed to present any evidence that his symptoms were a result of the product's manufacturing or design.

  • May 18, 2026

    Chancery Sends Sinovac Biotech Suit To Antigua And Barbuda

    The Delaware Chancery Court on Monday dismissed a shareholder suit against Sinovac Biotech Ltd. and several investors, ruling a fight over control of the China-based vaccine maker belongs in Antigua and Barbuda, where Sinovac is incorporated, rather than in Delaware courts.

  • May 18, 2026

    PBMs Tell Mich. Court They're Not To Blame For Opioid Abuse

    Pharmacy benefit managers told a Michigan federal court on Monday they are not responsible for opioid abuse because they do not control prescription drugs once they are sold to patients, as Evernorth Health, Express Scripts and other companies seek an exit from the state attorney general's public nuisance suit.

  • May 18, 2026

    Aetna Denied A Freeze On Trans Facial Surgery Order

    A Connecticut federal judge ordered Aetna to comply with a preliminary injunction requiring it to reconsider coverage denials affecting two transgender health plan participants who sought gender-affirming facial surgery, refusing to stay the insurer's compliance obligations during its pending appeal in the proposed class action.  

  • May 18, 2026

    Takeda Liable In IBS Drug Pay-For-Delay Trial

    A federal jury in Boston on Monday found Takeda Pharmaceuticals conspired with a generic-drug maker to delay the launch of a generic version of Takeda's anti-constipation drug, awarding purchasers $885 million, a figure that's expected to swell after a rule tripling plaintiffs' antitrust damages is applied.

  • May 18, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court this past week handled a broad mix of celebrity estate litigation, merger disputes, investor suits, record demands, sanctions fights and questions over corporate moves away from Delaware.

  • May 18, 2026

    Justices Deny Eli Lilly's Qui Tam Constitutional Challenge

    The U.S. Supreme Court on Monday declined to review Eli Lilly's $183 million trial loss to a whistleblower who claimed the drugmaker knowingly defrauded the government by underpaying Medicaid drug rebates.

  • May 18, 2026

    High Court Spurns Pharma Challenges To IRA Drug Price Talks

    The U.S. Supreme Court rejected six petitions Monday from pharmaceutical giants seeking to bring down the Medicare drug price negotiations established as part of the Inflation Reduction Act three years ago.

  • May 15, 2026

    Fed. Circ. Drops A Theme Song, Talks Guest Judges

    The Federal Circuit's full lineup came together Friday to provide practitioners with insight about their experience sitting on other courts, in a conference where the chief judge dropped the court's first (and only) single.

  • May 15, 2026

    Med Device Groups 'Overshot' In Fair Use Args, Judge Says

    A judge on a D.C. Circuit panel said a set of industry groups covering the advanced medical device industry might have "overshot" in a challenge to a Library of Congress exemption that said use of copyrighted software for the purpose of repairing those devices fell under fair use, since the groups tried to lump the software that merely operates the machines into the case.

  • May 15, 2026

    Pharmacies Stuck With CVS Arbitration Mandate At 9th Circ.

    A Ninth Circuit panel refused Friday to let four independent pharmacies avoid arbitrating their antitrust claims that CVS exploited a Medicare loophole to charge them exorbitant fees, standing by a district court's conclusion that just because parts of the arbitration agreement were unconscionable doesn't negate the entire thing.

  • May 15, 2026

    Edwards Investors Sue In Chancery Over $16.4B Stock Drop

    A stockholder has sued Edwards Lifesciences Corp.'s current and former leaders in Delaware Chancery Court, claiming they misled investors about growth prospects for the medical device company's key artificial heart valve business before a July 2024 disclosure wiped out more than $16.4 billion in shareholder value.

  • May 15, 2026

    Texas Hospital Creates 'De-Transition Clinic' After Settlement

    The Texas attorney general announced a settlement with Texas Children's Hospital that will see the creation of a detransition clinic, saying Friday that the hospital will pay $10 million for billing Texas Medicaid for "illegal 'gender-transition' interventions."

  • May 15, 2026

    4th Circ. Hands Express Scripts Jury Trial In W.Va. Opioid Suit

    The Fourth Circuit on Friday issued a writ of mandamus backing Express Scripts Inc.'s right to a jury trial in litigation over the pharmacy benefit manager's alleged role in contributing to the opioid crisis in West Virginia.

  • May 15, 2026

    Insurer Owes No Coverage In Ill. Genetic Testing Fraud Suit

    An insurer does not have to defend an embryo storage lab against a proposed class action alleging it used deceptive marketing to sell genetic testing services to IVF patients, because misleading promotion doesn't fall under the lab's coverage, an Illinois federal judge has ruled.

  • May 15, 2026

    $19.2M Joint Juice Deal Ends Calif. False Ad Suit

    A California federal judge has given final approval to a nearly $19.2 million settlement to end more than a decade of litigation alleging that the makers of Joint Juice misled consumers about its health benefits.

Expert Analysis

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

  • Assessing Compliance Risks Around TrumpRx Participation

    Author Photo

    As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.